Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Ryan Ramanujam"'
Autor:
Richard Nicholas, Jeff Rodgers, James Witts, Annalaura Lerede, Tim Friede, Jan Hillert, Lars Forsberg, Anna Glaser, Ali Manouchehrinia, Ryan Ramanujam, Tim Spelman, Pernilla Klyve, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Helmut Butzkueven, Anneke Van Der Walt, Vladimir Bezlyak, Carol Lines, Rod Middleton
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising
Externí odkaz:
https://doaj.org/article/94019eea78bf46cdb31bf422481b6086
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-18 (2020)
Abstract Background Machine learning models for repeated measurements are limited. Using topological data analysis (TDA), we present a classifier for repeated measurements which samples from the data space and builds a network graph based on the data
Externí odkaz:
https://doaj.org/article/c8919804eef949028b416aaef27e8ed0
Publikováno v:
Frontiers in Applied Mathematics and Statistics, Vol 7 (2021)
Exciting recent developments in Topological Data Analysis have aimed at combining homology-based invariants with Machine Learning. In this article, we use hierarchical stabilization to bridge between persistence and kernel-based methods by introducin
Externí odkaz:
https://doaj.org/article/84a516fddb8b498c89b25eaf7de664dd
Autor:
Ali Manouchehrinia, Anna Karin Hedström, Lars Alfredsson, Tomas Olsson, Jan Hillert, Ryan Ramanujam
Publikováno v:
Frontiers in Neurology, Vol 9 (2018)
Both high body mass index (BMI) and smoking tobacco are known risk factors for developing multiple sclerosis (MS). However, it is unclear whether BMI, like smoking, is a risk factor for the secondary progressive (SP) course. We, therefore, sought to
Externí odkaz:
https://doaj.org/article/98b79cc343df495d933271004b15c731
Autor:
Jenny Link, Ryan Ramanujam, Michael Auer, Malin Ryner, Signe Hässler, Delphine Bachelet, Cyprien Mbogning, Clemens Warnke, Dorothea Buck, Poul Erik Hyldgaard Jensen, Claudia Sievers, Kathleen Ingenhoven, Nicolas Fissolo, Raija Lindberg, Verena Grummel, Naoimh Donnellan, Manuel Comabella, Xavier Montalban, Bernd Kieseier, Per Soelberg Sørensen, Hans-Peter Hartung, Tobias Derfuss, Andy Lawton, Dan Sikkema, Marc Pallardy, Bernhard Hemmer, Florian Deisenhammer, Philippe Broët, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn, ABIRISK Consortium
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0170395 (2017)
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monito
Externí odkaz:
https://doaj.org/article/c098f1a316884e999aa568f4cc0fc10e
Autor:
Delphine Bachelet, Signe Hässler, Cyprien Mbogning, Jenny Link, Malin Ryner, Ryan Ramanujam, Michael Auer, Poul Erik Hyldgaard Jensen, Nils Koch-Henriksen, Clemens Warnke, Kathleen Ingenhoven, Dorothea Buck, Verena Grummel, Andy Lawton, Naoimh Donnellan, Agnès Hincelin-Mery, Dan Sikkema, Marc Pallardy, Bernd Kieseier, Bernard Hemmer, Hans Peter Hartung, Per Soelberg Sorensen, Florian Deisenhammer, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn, Philippe Broët, ABIRISK Consortium
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0162752 (2016)
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospecti
Externí odkaz:
https://doaj.org/article/f42ed773756e4b9bb482310f2683d0bf
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e71614 (2013)
The number of identified genetic variants associated to complex disease cannot fully explain heritability. This may be partially due to more complicated patterns of predisposition than previously suspected. Diseases such as multiple sclerosis (MS) ma
Externí odkaz:
https://doaj.org/article/9f9ca36b64d941418a4f5a08f91f932a
Autor:
Matilde Oviedo Querejazu, Nicky Dunn, Ryan Ramanujam, Malin Ryner, Michael Auer, Poul Erik Hyldgaard Jensen, Florian Deisenhammer, Anna Fogdell-Hahn
Publikováno v:
Multiple sclerosis and related disorders. 63
Interferon beta (IFNβ) is a first line therapy for treatment of multiple sclerosis (MS). However, up to 47% of treated patients will develop neutralizing anti-drug antibodies (NAbs) against IFNβ, which at high titres can inhibit the therapeutic eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95693ba692c6549077ea56d8bc24426
https://pubmed.ncbi.nlm.nih.gov/35508100
https://pubmed.ncbi.nlm.nih.gov/35508100
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9:205521732311535
Background To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::496df9527ec045ab3a1aedce973f7c65
https://doi.org/10.1177/20552173231153557
https://doi.org/10.1177/20552173231153557
Autor:
Michael Guger, Bernd C. Kieseier, Bernhard Hemmer, Kathleen Ingenhoven, Finn Sellebjerg, Luca Piccoli, Verena Grummel, Philippe Broët, Hans-Peter Hartung, Elisa Bertotti, Sebastian Spindeldreher, Signe Hässler, Marc Pallardy, Michael Auer, Manuel Comabella, Blanca Fernandez-Rodriguez, Orhan Aktas, Christina Hermanrud, Claudia Sievers-Stober, Clemens Warnke, Anna Fogdell-Hahn, Eva Havrdova, Naoimh Donnellan, Marcia Gasis, Michael Khalil, Daniel Kramer, Petra Nytrova, Sandra Rathmaier, Malin Ryner, Ryan Ramanujam, Xavier Montalban, Delphine Bachelet, Dorothea Buck, Pierre Dönnes, Per Soelberg Sørensen, Andy Lawton, Tobias Derfuss, Poul Erik Jensen, Florian Deisenhammer, Nicolás Fissolo, Jenny Link, Raija L.P. Lindberg, Begoña Oliver-Martos
Publikováno v:
Journal of Neuroimmunology. 326:19-27
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d84aa666d5b8da164f61c980c51d554
https://doi.org/10.1016/j.jneuroim.2018.11.002
https://doi.org/10.1016/j.jneuroim.2018.11.002